In this podcast, UROONCO BCa chief editor Dr. Benjamin Pradere (FR) talks to Prof. Siamak Daneshmand (US) from the Keck School of Medicine, University of Southern California. Prof. Daneshmand answers questions about the SunRISe-1 trial, which he presented at the 'late-breaking oncology abstract session' during AUA2023.

He discusses the study design, and delivers preliminary results from SunRISe-1 in patients with BCG (Bacillus Calmette-Guérin) unresponsive high-risk non–muscle-invasive bladder cancer receiving TAR-200 in combination with cetrelimab, TAR-200, or cetrelimab alone.

The promising findings from TAR-200 monotherapy showed an overall complete response rate of 73% in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) who were unresponsive to BCG. Prof. Daneshmand says the treatment was well-tolerated. Additionally, cetrelimab monotherapy demonstrated safety and efficacy profiles consistent with other anti-PD-L1 treatments in this disease setting.